🇺🇸 FDA
Patent

US 7795305

CDDO-compounds and combination therapies thereof

granted A61KA61K31/203A61K31/275

Quick answer

US patent 7795305 (CDDO-compounds and combination therapies thereof) held by The Board of Regents of the University of Texas System expires Mon Sep 09 2030 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Board of Regents of the University of Texas System
Grant date
Tue Sep 14 2010 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Sep 09 2030 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
12
CPC classes
A61K, A61K31/203, A61K31/275, A61K45/06